2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.16 Clinical Outcome of HER2-mut NSCLC Treated with First-Line Immunotherapy-Based Regimens versus Chemotherapy/HER2-TKIs

P4.11E.16 Clinical Outcome of HER2-mut NSCLC Treated with First-Line Immunotherapy-Based Regimens versus Chemotherapy/HER2-TKIs

Back to course

Pdf Summary

The study focused on assessing first-line treatments for advanced non-small-cell lung cancer (NSCLC) with HER2 mutations, comparing immunotherapy-based regimens with chemotherapy and HER2-targeted tyrosine kinase inhibitors (TKIs). The research aimed to address the lack of approved first-line targeted therapies for HER2-mutated NSCLC and the ongoing debate over whether immunotherapy should be prioritized over traditional approaches.<br /><br />A retrospective analysis was conducted on patients with primary HER2-mutated NSCLC who received first-line treatments at Guangdong Provincial People’s Hospital between January 2016 and December 2023. The study excluded patients with certain other oncogenic alterations like EGFR, BRAF, and KRAS mutations or specific gene fusions. Patients were categorized into three groups based on their treatment type: Group I received a combination of immunotherapy and chemotherapy, Group C received anti-angiogenic treatment with chemotherapy, and Group T underwent targeted therapy with pyrotinib or afatinib.<br /><br />The study included 160 patients with HER2 mutations and locally advanced or advanced NSCLC, observing a median follow-up of 37.1 months. Most patients in Group I received a combination of immunotherapy and chemotherapy, with few treated with immunotherapy alone. Group I showed a median progression-free survival (mPFS) of 8.8 months and a median overall survival (mOS) of 42.3 months.<br /><br />The results suggested that first-line immunotherapy-based regimens potentially improve clinical outcomes compared to chemotherapy and existing targeted therapies in patients with HER2-mutated NSCLC. The study highlights ongoing clinical trials comparing these novel first-line immunotherapy treatments with chemotherapy to further evaluate their efficacy.

Asset Subtitle

Hai-Yan Tu

Meta Tag

Speaker Hai-Yan Tu

Topic Metastatic NSCLC – Immunotherapy

Keywords

NSCLC

HER2 mutations

immunotherapy

chemotherapy

tyrosine kinase inhibitors

first-line treatments

retrospective analysis

progression-free survival

overall survival

clinical trials